InMed Pharmaceuticals Inc. (INM) Shareholder/Analyst Call Prepared Remarks Transcript
Summarize this article with:
SA Transcripts157.4K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call InMed Pharmaceuticals Inc. (INM) Shareholder/Analyst Call December 17, 2025 7:01 PM EST Company Participants Eric Adams - President, CEO & Director Conference Call Participants Sean Gillis Presentation Operator Hello, and welcome to InMed Pharmaceuticals, Inc. 2025 Annual General Meeting of Shareholders. I will now turn the call over to Eric Adams, CEO. Please go ahead. Eric AdamsPresident, CEO & Director Thank you. Ladies and gentlemen, the annual general and special meeting of InMed Pharmaceuticals will now come to order. My name is Eric A. Adams. I'm the President, CEO and a Director of InMed Pharmaceuticals. I will act as Chair of this meeting. I ask that Sean Gillis of Norton Rose Fulbright Canada LLP and Legal Counsel to the company, act as Secretary of this meeting. And I appoint Jessica De La Torre of Odyssey Trust Company as scrutineer of this meeting. The Secretary has tabled for inspection by any shareholder or proxyholder a sworn declaration that the notice calling this meeting and the accompanying materials, including the information circular were mailed to all security holders of record as of October 22, 2025. I will dispense with calling for a reading of the Notice of Meeting and direct that a copy of the declaration be kept by the secretary with the minutes of the meeting. The scrutineer has submitted a report on attendance to the Secretary. The Secretary will now read the scrutineer's report.
Sean Gillis The scrutineer's report reads as follows. A quorum of shareholders is present for the transaction of business at this meeting if at least 2 persons are present in person and holding or representing, by proxy, not less than 33.3% of the shares entitled to vote at the meeting. I've been advised by the scrutineers that there are 43 shareholders present today, either in person or by